drug

Acetazolamide

MeSH D000086
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Vishwajit Nimgaonkar, MD PhD
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

1
Acetazolamide for Treatment Resistant Schizophrenia
NCT04887792Phase 1, Phase 2Recruiting

KOLs & investigators

1
Vishwajit L. Nimgaonkar, M.D., Ph.D.

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Vishwajit Nimgaonkar, MD PhD
company
trial
Acetazolamide for Treatment Resistant Schizophrenia
PHASE1, PHASE2
trial
indication
Schizophrenia
indication
Schizo Affective Disorder
indication
Schizophrenia
indication
Psychotic Disorders
indication
KOL
Vishwajit L. Nimgaonkar, M.D., Ph.D.
KOL score —
person